Anixa is focused on harnessing the bodyâs immune system in the fight against cancer. Anixaâs therapeutics portfolio includes a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T, and a cancer vaccine technology focused specifically on triple negative breast cancer (TNBC), the most lethal form of the disease. Anixaâs diagnostics portfolio includes the CchekTM liquid biopsy technology, a series of inexpensive non-invasive blood tests for early detection of solid tumors based on the bodyâs immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Source
No articles found.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated t...
electroCore, Inc. is a commercial stage bioelec...
SCWorx offers an advanced software solution for the management of health care prov...
SCWorx offers an advanced software solution for...
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the ...
AcelRx Pharmaceuticals, Inc. is a specialty pha...
Microbotâ˘, which was founded in 2010 and commenced operations in 2011, became a ...
Microbotâ˘, which was founded in 2010 and comm...
Join the National Investor Network and get the latest information with your interests in mind.